St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study is a 3-arm pilot, randomized, double-blinded, placebo-controlled study of low-dose
naltrexone and gabapentin versus placebo among HIV-positive persons with heavy alcohol use
and chronic pain to provide estimates of their effects on 1) pain; 2) inflammation; and 3)
measures of HIV control. Participants will be followed for 12 weeks. Assessments of study
outcomes will be compared at week 8 (end of treatment phase).
Phase:
Phase 2
Details
Lead Sponsor:
Boston Medical Center
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)